<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 375 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page374.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=375">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 375 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 375</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=375"><img src="../thumb/375.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>338 / 2020-04                                                                 Biologicals - 26
                                             nd
   Contraindications: Pregn., neomycin hypersens., any febr.resp.illn./  mycin/polymyxin B antibiot., 2  dos.poss.aft sympts.resolv.in event   Formulat.to contain 2,2 µg of each saccharide for serotypes 1,3,4,5,6A,
   other act.febrile infect., act. untreat.TB, concom.immunosuppress.  of vomit.& diarrh., inactiv.poliomyelit.vacc.recomm.in immune defic.,   7F,9V,14,18C,19A,19F,& 23F, and 4,4 µg of saccharide for serotype
   ther.excl. corticoster.for Addisons dis., bld.dyscras, leukaem., lym-  not to be admin.within 3 mnths.of prior immunoglobulin., strict pers.  6B/0,5 ml dos. Approx.28 µg
   phomas of any type, malign neoplasma affect.bone marr./lymphat.  hygiene of contacts of recently immun.babies.  Indications: Invas.dis./pneumon.& otitis med. prev. caus.by Strepto-
   syst., prim/ acquir. immunodefic., fam.hist.of congenit./ heredit. im-  coccus pneumoniae serotypes 1,3,4,5,6A,6B,7F,9V, 14,18C,19A,19F,&
   munodefic.until.immune competence demonstrat.  PNEUMOVAX 23, MSD [P/S]  23F in infts.,childr & adolesc.; prev.of pneumoocc. dis. (incl.pneum.&
   Side effects: Nasopharyngit., URTI, vir.infect., asept.meningit.,   Pneumococcal.vaccine, polyvalent.  invas.dis.) in adults ≥ 18 yrs. caused by Streptococcus pneumonia
   atypic.measles, epididymit., orchit., otit.med, parotit., rhinit., subac.  Indications: Immunis.against pneumococcal.dis. caus.by types of   serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23F.
   scleros. panencephalit., lymphadenopathy, thrombocytopaen., ana-  pneumococci in vacc.  (S2) SUSP.FOR INJ, 44/30.1/0002
   phylax., irritab., ac. dissemin. encephalomyelit., afebrile convuls.,   (S4) INJ. T/30.1/0544. 25 mcg/0,5 ml dose.  715858-001: 28 µg/0,5 ml, 1xpre-fill.syr., R879,99
   atax., dizzin., febrile convuls.in childr., Guillain-Barrè syndr., headache,   755826-027: 1 Sngl.dose, R191,65  Dosage: May be admin. simultan.with other paed. vacc.in accord.
   measles incl.body encephalit., ocul.palsies, optic neurit., paraesthes.,   Dosage: 0,5 ml SC/IM.  with immunisat. sched.at diff. sites. Has been admin.with rotavir.
   polyneurit., polyneuopathy, retrobulbar neurit., transver.myelit., syn-  Contraindications: Childr.und.2 yrs., IV & intraderm. use, safety in   vacc.& hepatit.A vacc.with no change to safety profile observ. Ad-
   cope, conjuctiv., retinit., nerve deafn., rhinorrh., bronch.sp., cough,   pregn. & lactat.not est., concom.Zostavax.  min.dos.of 0,5 ml IM only. Anterolat. thigh in infts.& deltoid musc.in
   pneumon., pneumonit., sore throat, diarrh., vomit., naus., skin rash,   Side effects: Loc., hypersens.& skin reacts., arthralg., asthen., fev.,   old.childr.& adults. Do not mix.with other vacc./prod.in same syringe.
   urticar., panniculit., purpura, skin indurat., Stev.-John.syndr., Henoch-  bld.dyscras., neurologic. disords.incl.Guillain-Barre syndr., CNS effs.  Data on interchangeabil.with other pneumococc conjug. vacc.with
   Scholein purpura, ac.haemorrhag.oed of infancy, arthrit., arthralg.,   Special precautions: Sev.reacts.poss.in adults if revaccinat.within   prot.carr.diff.from CRM 197 not avail.
   myalg., fev., inj.site reacts., vasculit.,  2 yrs., sev.compromis.card.& pulm.funct., febr.resp.illn., infect., requir.  Infts. & childr.aged 6 wks.-17 yrs (prior to 18th birthday):
   Warnings and special precautions: Infts.born to mothers who   antibiot. prophylax.not to be discont.aft.vaccin.  Inft.prim.vaccinat.consists of 3 dos.of 0,5 ml each at approx. 2-month
   had wild-type measles and vaccinat. at &lt;1 yr.may poss.not develop.  Warnings: Concom.immunosuppress.ther.(expect. ser. antibody   interv. follow. by a 4th dose of 0,5 ml at 12-15 mnths. of age. Custom.
                                                                  st
   sustain. antibody lev.when later revaccin.& infts.&lt;12 mnths. may fail.  respon.not obtain.)  age for 1  dos. is 2 mnths of age (but can be giv.as early as 6 wks) with
   to respond to measle compon.due to pres.of circulat.resid.matern.  POLYGAM, NBI [P/S]  interv.of 4-8 wks.betw.dos. Fourth dos.recomm.betw. 12-15 mnths.&
                                                                       rd
   measle antibod., theref.admin.2  dos.at 12-15 mnths if vaccin.und.   Human polyval.norm.immunoglobul.deriv.from pool. human plasma,   at least 2 mnths. aft. 3  dos.
                nd
   these condits., avoid pregn.x3 mnths.follow. vaccinat., appropr.ana-  test.& found non-react.to HBsAg & antibodies to HCV, HIV-1 & HIV-2   Alternat.when given as part of routine inft. immunisat.program a
   phylax.treatm.to be avail., indiv. convuls./fam.convuls.hist./cerebr.injur.  viruses. The manufact.method incl.cold ethanol fractationat. & pH4,0   3-dos. sched.may be consid. with 1st dose giv.from age of 2 mnths.,
                                                                         rd
   hist./ condits. where stress.from fev.to be avoid., eval. risk vs.benef.of   pepsin treatm.to furth. reduc.risk of viral transmiss. The pH4,0 pep-  2  dos. 2 mnths. later & 3 .dos.recomm.betw.11-15 mnths.of age.
                                                               nd
   vaccinat.pts.allerg.to egg & pts. with curr.thrombocytopen., monit.HIV   sin process has been validat.& shown to be effect. against envelop.  Preterm infts. (&lt;37 wks gestat.): Admin 4 dose (0,5 ml. each) begin.
   infect. vaccinees for vaccine-prev.dis.as immunisat.may be les effect.,   virus.HIV, HBV & HCV.  at 2 mnths. of age (but can be giv.as early as 6 wks) approx. 1 mnth.
   poss.transmiss.of rubella vir.via breast milk, lactat., poss.tempor.de-  Indications: Replacem.ther.in prim.antibody defic.states, myeloma/  apart  Fourth dos. recomm.at approx.12 mnths of age.
   press.of tuberculin skin sensitive., 100% protect.may not result, defer   chron.lymphocyt. leukaem. with sev.hypogammaglobulinaem.& re-  Prev.unvacc.infts.from 7-11 mnths: Admin. 2 dos. (0,5 ml each)
   for 3 mnths./long. follow.plasma/bld. transfus./immune ser.globulin   curr.infects., congenit.AIDS & recurr.infects.in childr., immunomodulat.   approx.1 mnth apart follow. by 3  dos.recom.in 2  yr.of life. &
                                                                                    nd
                                                                             rd
                                                                    nd
   admin, may be admin. at same time as live attenuat.Varicella vacc   in idiopath. thrombocytopen. purpura (ITP)/Kawasaki dis.& Guillain   &gt;2mnths aft. 2  dos.
   & inactiv.Hib if separat.sites used, allow 1 mnth betw. other live vir.  Barre Syndr., allogeneic bone marr.transplantat.  Prev.unvacc.childr.from 12-23 mnths: Admin. 2 dos(0,5 ml each)
   vacc., concur.DTP &/OPV not recomm. due to limit.data, revaccinat.at   (S4) IV INFUS, LYOPHIL.POWD.  at least 2 mnths apart.
   4-6 yrs.of age, women of child.bear.age to delay pregn. x3mnths., vac-  Z/30.2/367,368,369, 29/30.2/511.  Prev.unvacc.childr.2-5 yrs: One sngl.dos.
   cinat.recomm.for suscept.indiv. plann. travel abroad/high risk groups  800775-007: 1g, 50 ml glass bott., R691,18  Infts.&childr.prev.vaccinat.with pneumococcal 7-valent con-
   Interactions: Immune respons.from immune globul.poss.inter-  800783-018: 3 g, 100 ml glass bott., R1 382,34  jug.vacc.: Childr. start.immunisat.with pneumococcal 7-valent con-
                                                                                       ®
   fer.with                     813656-001: 6 g, 200 ml glass bott., R2 764,68  jug.vacc.may compl. immunisat.by switching to Prevenar 13  at any
                                                              point in sched.; Childr. 15 mnths.-5 yrs consid.completely immunis./
   ONVARA, MSD                  819670-006: 12 g, 400 ml glass bott., R5 529,36  or with any incompl.pneumococcal 7-valent conjug.vacc. sched.may
   Oka/Merck live attentuat.varicella virus  Dosage: IV admin. Dos.regim.given as guideline only depend.on indi-  receiv.1 Prevenar dos.to elicit immune resp.to 6 addit. serotyp.at least
   Indications: Varicella vaccinat.from 12 mnths & old.  cat.& IgG molecule in vivo half-life. Admin.immed.aft.reconstit.using   8 wks.aft.the fin. dose of pneumococcal 7-valent conjug.vacc.; To en-
   (S4) LYOPHIL.POWD.& SOLV.FOR INJ., 48/30.2/1059  administrat. set with in-line filter & airvent needle. (For renconstit.   sure adeq.protect.childr. aged 15-23 mnths. that receiv.only a sngle
   723131-001: 1350 pfu/0,5 ml dos., 1, R491,05  proced. see manufacturer’s package insert). Infus.rate recomm.calc.  dose of pneumococcal 7 valent conjug.vacc.before age of 12 mnths.
   Dosage: SC admin only. Admin.immed.aft. reconstit. & discard if   using a 20 drop/ml admin.set.  should rec. 2 dos.of Prevenar at least 2 months apart.
   not used within 30 min.      Commenc.at 10-20 drps./min.(30-60 ml/hr), incr.to 20-30 drps./  Childr 24 mnths to 17 yrs: 1 sngl. dos.irrespect. of prev.vaccinat.
   Childr: 12 mnths–12 yrs: Sngl.0,5 ml dos. Adolesc.13 yrs & old.&   min.(60-90 ml/hr)aft.15 min. Max.40-50 drps./min.(120-150 ml/hr)  with 1 or more doses of pneumococcal 7-valent conjug.vaccine. If
   adults: 0,5 ml at elect.date and 2  0,5 ml dos.4-8 wks.later.  if tol. Decr.infus rate/ stop admin.should adverse react.occur.until   pneumococcal 7-valent conjug.vacc.was prev. admin.wait at least
                 nd
   Contraindications: Gelat/neomycin hypersens., bld.dyscras., leu-  sympts. dissapp.  8 wks.bef.start. Prevenar
   kaem., any type lymphomas/other malign.neoplasms affect.bone   Recomm.infus.rate bas.on bm where advis: 0,01-0,02 ml/kg/min.for   Adults ≥ 18 yrs. (incl.those prev.vaccinat. with a pneumococc.
                                 st
   marr./lymphat.syst., immunosuppress.ther.incl.high dos.corticoster.,   1  30 mins.grad.incr.to max. 0,08 ml/kg/min.for remain.  polysacchar.vacc.): One sngl.dos.
   prim./ acquir.immunodefic.states, fam.hist.of congenit./heredit.im-  Replacem.ther.in immunodefic:  Spec. populat: Ref.to prod.lit.
   munodefic., act.untreat.TB, act.febrile illn.with fev.&gt;38,5°C, pregn.  Prim.immunodefic: Start.dos: 0,4-0,8 g/kg thereaft. 0,2-0,8 g/kg   Contra-indications: Diphth.tox.hypersens., safety in pregn.& lactat.
   Side effects: Loc.reacts., varicella-like rash, fev., U&Lresp.illn.,   every 2-4 wks.to obt.IgG trough lev.of at least 4-6 g/L  not est., safety & effectiven.in childr.bel.6 wks.not est.
   cough, irrit./nervousn., fatig., disturb. sleep, diarrh., loss of appetite,   Second.immunodefic: 0,2-0,4 g/kg every 3-4 wks. to obt.IgG trough   Side-effects: Infts.& childr.6 wks.- 5 yrs: Decr. appetite, irritabil.,
   otit., diaper -/contact rash, headache, teeth., malaise, abdom. pain,   lev.of at least 4-6 g/L  cry., drowsin., incr./ decr.sleep, restless, seiz.incl.febr.seiz., diarrh.,
   other rash, eye complaints, chills, lymphadenopathy, myalg., allerg.  Childr.with AIDS: 0,2-0,4 g/kg every 3-4 wks.  vomit., hypersens.reacts.incl.fac.oed./dyspn & bronchosp., skin rash,
   reacts., stiff neck, heat rash, insect bites, arthralg., eczema, dry skin,   Immunomodulation:  uritcar., fev., loc.reacts., hypoton./hyporespons.episode, anaphylact.
   dermatit., constipat., itch., febrile seiz., dizzin., anaphylax., necrotis.  ITP: 0,8-1 g/kg on day 1. Rep.once within 3 days if necess. OR 0,4 g/  react., angioneurot.oed., erythema multiforme.
   retinit.in immunocomprom. pts., N&V, aplast.anaem., thrombocty-  kg/day x2-5 days. Rep.if relapse occurs.  Adults ≥ 18 yrs: Decr.appet., headache, GI disords., hypersens.re-
   topen.incl. ITP, varicella, encephalit., CVA, trans.myelit., Guill.-Barre   Kawasaki dis: 2 g/kg as sngl.dos.in conjunct. with aspir.OR 1,6-2 g/  acts.incl.fac.oed., dyspn.& bronchosp., rash, joint/musc.pain, admin.
   syndr., Bells’palsy, atax., febrile & non febrile seiz., asept.meningit.,   kg in div.dos.x2-5 days in conjunct. with aspir.  site reacts., chills, fatig., fev., limit.arm movem., lymphadenopathy.
   paraesthes., pharyngit., pneum., Stev.John.syndr., erythema multi-  Guillain Barre syndr: 0,4 g/kg/day x3-7 days.  localis.to inj.reg.
   forme, Henoch-Schonlein purpura, second. bact.infects.skin & soft   Allogeneic bone marr.transplantat:  Warnings and special precautions: Treatm.of poss. anaphylact.
   tiss.infects., H.zoster      Graft vs.host dis.infect.treatm.& prophylax: Start.dos.0,5 g/kg   react.readily avail., postpon.in ac. sev.febrile illn., thrombocytopen./
   Warnings and special precautions: Treatm.for poss.anaphy-  wkly.start.7 days prior transplantat. & up to 3 mnths.aft.  any coagulat. disord./concom.anticoag.ther., protects only against
   lax.to be avail., protect.period unknown, transmiss.of vacc.vir.betw.  Persist.lack of antibody product: 0,5 g/kg every mnth.till lev.  serogroups of composit., not intend. for treatm.of act.infect., may not
   healthy vaccinees. report., vacc.receipt.to avoid close assoc. with   return.to norm.  protect all indiv., safety & immunogenicity data not avail.for childr.
   suscept.high-risk indiv.x6 wks., eval. benef.vs.risk of transmiss.to   Side effects: Poss.inhib. eff.of live vaccines, sensitisat., skin reacts.,   at high.risk for invas.pneumocc.dis & they may have reduc.antibody
   high-risk indiv., defer vaccinat x5 mnths foll.bld./plasma transfus./   loc.reacts., joint pain, myalg., faintn., revers.asept.meningit.syndr.,   respons.due to imp. immune responsiven., safety and immunogenic-
   immune globul/varicella zoster immune globulin admin., avoid   burn. sensat. in head, leg cramps, N&V, hypotens., tachycard, dyspn.,   ity data not avail.for indiv.in immunocompromis. groups & vaccinat.
   pregn.x3mnths.follow.vaccinat., caut. in nurs.moth.as some vir.are   wheez.,thrombot.events, revers. haemolyt. aneam./haemolys., ac.ren.  should be individ., pneumonocc. conjug.vacc.does not replace use of
   secret.in breast milk.       fail., fev., back/ headache, malaise, fatig., chest pain, chills, fall in BP&   23-valent pneumonocc.polysaccharide vacc.in childr. 24 mnths.or old.
   Interactions: Do not admin.any immune globul.for 2 mnths.thereaft.  anaphylact.reacts., incr.risk of inflammat. reacts.in pts.with agamma-  who are immunocomprom., data on sequent. vaccinat. with Prevenar
   unless.use outweighs vaccinat. benef., avoid salicylates x6 wks.aft.  globulinaem. /sev.hypogammaglobulinaem dur.1st IV infus.esp.if rapid.  13 follow.by 23-valent pneumococc. polysacchar.vacc.not avail., data
   vaccinat.as Reye syndr.report.follow.its use dur.wild-type varicella   Special precautions: Pres.of IgA antibod./ select. IgA defic.pts.,   on sequent.vaccinat.with pneumocc.7-valent conjug vacc.follow.by
   infect., observ.1 mnth interv.betw.2 live vir.vacc.if not given concom.  admin.live vacc.3 mnths. aft. immunoglobul., adverse reacts.more   PPV23 limit., consid.potent. apnoea risk when admin.prim.immuni-
                                          st
   OPV-MERIEUX, Sanofi Aventis [P/S]  freq.when admin. for 1  time/when immunoglobul.prod. switch /   sat.ser.to prem. infts., consid.need for monitor.≥ 48 hrs. aft.vaccinat.
                                long inter.betw.infus., anaphylax.treatm. avail. dur.admin., do not
                                                              for very prem.infts.born &lt;30 wks.of gestat., no data in childr.& ado-
                     (6.0)
   Type 1 poliovirus(LS-c 2 ab strain) at least 10  CCID50, type 2 polio-  total.excl.poss.of infect. agents/ unknown or emerg.virus.& other   lesc on concomit. admin. with HPV vacc/ MCV4 vacc./Tdap vacc.
                   (5.0)
   virus (P712, CH, 2 ab strain) at least 10  CCID50, type 3 poliovirus   pathogens, poss.vol.prob.esp.with high.dos.in pts. with limit.card.  See also MDR page 635.
                (5.8)
   (Leon 12a1 b strain) at least 10   CCID50/0,1 ml dose.  funct., transit.rise.of various passive. tranfer.antibod.in bld., pregn.&
   Indications: Prevent.of poliomyelit.  lactat., 1  infus. of 3-12 g admin must be as 3% sol., side-effect risk   PRIORIX, GSK [P/S]
                                    st
   (S2) SOL. 27/30.1/0531.      lessen.if infus.rate kept low., in cert. pt. groups determin.max.safe   Lyophilised live attenuated virus vaccine, Measles virus of Schwarz
   841307-016: 10x10 dose vial, R486,98  infus.rate bas.on pts. body mass as given above, thrombot.events   strain not less than 10 CCID 50; Mumps virus of RIT 4385 strain not
                                                                       3.0
   Dosage: Admin.orally.1 dos.=0,1 ml=2 drps. Check heat sensit.vacc.  in elderly /pts with signs of cerebral/card.ischaem/ overweight &   less than 10 CCID 50, rubella virus of Wistar RA 27/3 strain not less
                                                                   3.7
   vial monit.(VVM) bef.use     sev.hypovolem.pts., don’t combine with other IV preps., migr.hist./  than 10  CCID 50/0,5 ml.
                                                                 3.0
   Prim.vaccinat: 1st dos.at birth, then at 6, 10, 14 wks of age follow.  pts.given high.dos. at high.risk of asept.meningit.syndr,pts.at risk of   Indications: Act.immunisat.against measles, mumps & rubella in
   by addit dos.at 18 mnths.    develop. ac.ren.fail., pre-exist.ren.insuff., diabet. mellit., pts.&gt;than   2nd year of life, booster at 4-6 yrs.
   Booster: 5 yrs.              65 yrs., vol.deplet., sepis., paraproteinaem., concom.nephrotox.  (S2) INJ, 33/30.1/0346
   Contraindications: Ser.reacts.aft.prev.admin., postpone vaccinat.  meds., overweight. pts., ensure adeq.hydrat./avoid concom. loop   700772-001: 1 x mono dos.vial+dil., R212,96
   in case fev./ac.dis., congenit./ acquir.immune defic., contacts of im-  diuret./monit.ren.funct.& consid.dos. adjust.to minimise ren.fail.risk.  Dosage: Do not mix.with other vacc.in same syringe. Allow disinfect.
   munosuppress. pts., progress.malign.illn., pregn.          agent to evapor.bef. admin. Can be giv.at same time as live atten.
   Side effects: Fev., rigors, asthen., myalg., arthralg., paraesthes.,   PREVENAR 13, (Pfizer) Wyeth [P/S] &  varicella vacc.at diff.site. Admin.0,5 ml of reconstit. vacc.SC immed./
   paresis, neurit., myelit., except. post vaccinat.paralys.due to revers.  Streptococcus pneumoniae capsular antigen saccharides of serotypes   within 8 hrs. May be giv.IM.
   of vaccine virus to neurovirul.  1,3,4,5,6A,6B,7F,9V, 14,18C,19A,19F,& 23F indiv.conjugat.to non-tox.   (S4) TETRA INJ, 43/30.1/0127
   Special precautions: Do not inj., hypersens.to neomycin/ strepto-  diphther.CRM  197 prot.  Live attenuat virus vacc, Measles virus of Schwarz strain not less</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page374.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page370.html">370</a>&nbsp;&nbsp;&nbsp;<a href="page371.html">371</a>&nbsp;&nbsp;&nbsp;<a href="page372.html">372</a>&nbsp;&nbsp;&nbsp;<a href="page373.html">373</a>&nbsp;&nbsp;&nbsp;<a href="page374.html">374</a>&nbsp;&nbsp;&nbsp;<a href="page375.html">375</a>&nbsp;&nbsp;&nbsp;<a href="page376.html">376</a>&nbsp;&nbsp;&nbsp;<a href="page377.html">377</a>&nbsp;&nbsp;&nbsp;<a href="page378.html">378</a>&nbsp;&nbsp;&nbsp;<a href="page379.html">379</a>&nbsp;&nbsp;&nbsp;<a href="page380.html">380</a>
             </td>
             <td width="35%"><a href="page376.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page376.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
